Nokdirna (Desmopressin)

Desmopressin, the active ingredient in Nokdirna, is a vasopressin analog presented as a sublingual formulation for sublingual use. It treats central diabetes insipidus, nocturnal enuresis, and mild hemophilia A or von Willebrand disease in appropriate patients.

GNH USA supplies Nokdirna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides reliable global distribution to meet clinical demand. All batches are manufactured in accordance with EU GMP guidelines and are fully traceable.

Desmopressin acts on the antidiuretic pathway to reduce urine output and improve hemostasis, making it useful in several endocrine and bleeding disorders. It is administered sublingually to ensure rapid absorption. - Central diabetes insipidus: reduces excessive urine production, helping maintain fluid balance and prevent dehydration. - Nocturnal enuresis: decreases nighttime bedwetting episodes in children and adolescents, supporting better sleep and quality of life. - Mild hemophilia A and von Willebrand disease: raises plasma factor VIII and von Willebrand factor levels, enhancing clot formation and reducing bleeding risk.

Desmopressin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hyponatremia: low blood sodium levels, often presenting with mild fatigue or confusion. - Headache: mild to moderate head pain occurring shortly after dosing. - Nausea: transient stomach upset or queasiness. - Facial flushing: temporary redness of the face and neck.

Serious or Rare Side Effects: - Severe hyponatremia: markedly low sodium that can cause seizures, coma, or cerebral edema. - Water intoxication: excessive water retention leading to rapid weight gain and pulmonary edema. - Allergic reaction: rash, itching, swelling, or anaphylaxis in rare cases.

When prescribing desmopressin, clinicians should consider several safety precautions to minimize risk. - Monitor serum sodium: check sodium levels before treatment and periodically during therapy. - Adjust dose in renal impairment: reduce dosage or increase monitoring in patients with reduced kidney function. - Avoid concomitant antidiuretics: do not combine with other drugs that increase water retention, such as thiazide diuretics. - Caution in elderly: older patients are more susceptible to hyponatremia and should be closely observed. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Desmopressin can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: reduces desmopressin’s antidiuretic effect, potentially leading to treatment failure. - NSAIDs: may potentiate water retention and increase risk of hyponatremia. - Thiazide diuretics: enhance antidiuretic action, raising the chance of severe hyponatremia.

Moderate Interactions (Monitor Closely): - SSRIs: combined use can increase hyponatremia risk; monitor sodium levels. - ACE inhibitors: may augment antidiuretic effect, requiring sodium monitoring.